Critical Care | Daxor

Blood Volume Measurements Improved Survival

Prospective randomized control trial in Surgical ICU

N=100, 70% Septic Shock / Sepsis / ARDS

66% reduction in mortality

20% reduction in LOS

36 hour earlier treatment decisions

44% change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

66% reduction in mortality

44% change in treatment strategy

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

Persistently Elevated Albumin Transudation Rate Associated With Higher Mortality

Rate at which the albumin transudates out of circulation shown to be predictive of ICU mortality in cohort with 70% respiratory failure.

Retrospective Study in Surgical ICU

N = 164

Civetta, Taylor, & Kirby’s Critical Care, Fourth Edition 2009